E2F1 and neoplasm: As we have previously reported, this treatment regimen markedly prolongs survival of tumor-bearing mice and is associated with reduced E2F1 and FASN expression (Fig. 1c) and with diminished proliferation in the tumors, as indicated by reduced levels of cyclin D2 (Fig. 1c).